GlaxoSmithKline has appointed Emma Walmsle as chief executive designate. Walmsley, who is currently CEO of GSK's consumer healthcare division, will take over from Andrew Witty when he retires on 31 March.
She will join the GSK board of directors from 1 January.
Chairman Philip Hampton, GSK Chairman, said: "I am very pleased to announce Emma's appointment, after what has been a very thorough and rigorous global selection process carried out by the GSK board of directors.
"Emma is an outstanding leader with highly valuable experience of building and running major global businesses and a strong track record of delivering growth and driving performance in healthcare.
"Under Andrew's leadership, GSK has successfully developed into a company with market-leading positions in pharmaceuticals, vaccines and consumer healthcare. These provide excellent platforms for sustainable, long-term growth, and we are confident Emma will successfully build on these strengths." At 8:11am: (LON:GSK) GlaxoSmithKline PLC share price was -18.5p at 1627p